New Protein G Biosensor Available for the Octet Platform!
Sriram Kumaraswamy, Product Manager
Immunoglobulin-binding proteins such as Protein A, Protein G and Protein L are commonly used to purify, immobilize or detect immunoglobulins. They have different binding profiles with respect to species, antibody type, and the portion of the antibody that is bound. Protein A biosensors are currently used for human and other IgG quantitation on the Octet platform in a variety of applications including cell line development, clone selection, process optimization and production monitoring.
The new Protein G biosensor is useful for quantifying numerous species of IgG including murine, goat and bovine in the presence of other types of immunoglobulins or protein contaminants. It complements the use of Protein A biosensors due to its high binding affinity for rodent and many other mammalian species’ IgGs which cannot be detected with Protein A.
While native Protein G will bind to albumin in addition to immunoglobulins, the recombinant form of Protein G used in the biosensor has had the albumin- and cell-surface protein binding domains removed, to eliminate albumin binding interference. IgG can be quantified on the Protein G biosensor from buffer solutions, from cell culture media that has been appropriately diluted, or in the presence of media containing biotin (for example, RPMI).
The Protein G biosensor is specifically designed for use in quantitation assays on the Octet platform. Immunoglobulin binding to the biosensor is monitored in real time using an Octet system. The real-time binding information is used to quantify the amount of IgG by comparing the binding rate of the unknown sample to a standard curve of the binding rates of known concentrations of the same species and subtype of immunoglobulin. Protein G’s binding kinetics vary greatly depending on both the species and the subtype of IgG, therefore it is critical that the IgG used as a calibration standard be the same species and subtype as the antibodies that are being quantitated.
IgG can be detected on the Protein G biosensor from 0.05 µg/mL to 2000 µg/mL in Sample Diluent. Typically, assays run at 200 rpm shaking speed and a 2-minute read time provide a dynamic range of 0.5 µg/mL to 2000 µg/mL. By extending the read time to 5 minutes and increasing the shaking speed to 1000 rpm, the detection range is lowered to 0.05 µg/mL to 300 µg/mL. As an added benefit, a low-pH buffer such as 10 mM Glycine, pH 1.7 to 2.0, can be used to regenerate the Protein G biosensor.
For more information on the Protein G biosensor, visit our biosensor page. To request a quote for Protein G biosensors, please visit our ordering page.
ForteBio Joins Forces with Tecan to Automate Label-free Assays for Bioprocess and Drug Discovery Applications
Kevin Moore, Director of Market and Application Management for BioPharma, Tecan
ForteBio has chosen Tecan as its preferred automation partner for real-time, label-free assays to support bioprocess and drug discovery workflows. The two companies have worked together to integrate the new ForteBio Octet® 384 platform, consisting of the Octet RED384 and the Octet QK384, on Tecan’s Freedom EVO® liquid handling workstations. The result is a robust and fully integrated off-the-shelf solution that enables Octet customers to automate sample handling and process batches of assay plates for Dip and Read™ biosensor assays, offering increased walkaway time and the option of automated liquid handling for assay plate setup.
This collaboration forms part of Tecan’s ongoing commitment to the bioprocessing market, working with leading technology providers to offer customers advanced automation solutions, and bringing the advantages of the Freedom EVO platforms to the fast growing area of label-free, real-time detection.
Label-free techniques avoid the generation of artifacts through label interference, and the Octet instruments’ proven track record of performance and reliability fitted well with Tecan’s goals, enabling high throughput measurements for protein-protein, protein-peptide, protein-small molecule and fragment screening assays. By creating an extension plate to mount the Octet 384 securely onto the side of any Freedom EVO platform, customers will be able to take advantage of ForteBio’s proprietary biolayer interferometry (BLI) technology in a format that best meets their exact needs, offering an unrivalled level of flexibility for walkaway, real-time analysis.
A robotic manipulator arm automates handling and transport of plates and sensor trays, and an 8-channel liquid handling arm with either fixed or disposable tips is used to prepare assay plates. A MultiChannel Arm™ (MCA) with a 384- or 96-channel pipetting head can also be specified to further increase throughput and efficiency. The Octet platform also complements a range of other technologies within Tecan’s portfolio of bioprocessing solutions — covering everything from construct generation to protein purification — providing customers with a reliable method for product quantitation and quality assurance at almost every step.
This close collaborative partnership will ensure that customers receive the best solution available, combining the advanced liquid handling and scheduling capabilities of the Freedom EVO workstation with the innovative Dip and Read biosensors of the Octet 384 platform. This integrated set-up offers a straightforward route to reliable and reproducible performance of label-free assays, with the option to automate as much of the workflow as the customer desires.
To learn more about automation on the Octet platform, visit our automation page; learn more about Tecan’s bioprocessing solutions at www.tecan.com/drugdiscovery.
For more information or to find out how to order custom biosensors, please email me at email@example.com or visit our custom services page.
Building an Enduring Life Science Tools Company
Joe Keegan Ph.D., President and CEO
It is with great pleasure that I communicate some of our achievements during the first half of 2010. Driven by our initial product introduction of the Octet QK five years ago, followed by the higher-performing Octet RED in 2008 and the successful launch of the automation-friendly Octet 384 platform one year ago, ForteBio has achieved solid growth across all geographies and life science segments. We now have a global direct selling and product support team. Our extensive customer base, supported by 13 biosensor chemistries and assay kits means that we have an impact on drug discovery, development and bioprocess applications across the life sciences. We have expanded our initial key application in protein-protein kinetic characterization to a broad range of direct quantitation and real-time screening solutions including small molecule and fragment screening assays.
We have now added to our consumable offering the Dip and Read™ Protein G biosensor, enabling direct quantitation of IgG from mouse, rodent or rabbit cell line preps, strengthening our bioprocess and cell line development tool set. Earlier this year, we launched an enhanced version of our popular Octet QK instrument, the more sensitive and wider dynamic range Octet QKe. Octet Software Version 6.3 was launched simultaneously, enabling all five Octet instruments in our product line with additional fitting modes, analysis capabilities and automation tools. At ForteBio, we are committed to a product leadership strategy, aggressively investing in product development in order to deliver innovative, high quality new products — instruments, consumables, and software — that contribute to increasing performance and productivity in the laboratory.
Complimenting the products we offer, the beginning of 2010 saw ForteBio launch a Custom Biosensor business. Supporting our customers’ desire to develop proprietary biosensor assays, ForteBio will develop and ship custom Dip and Read biosensors for off-the-shelf use in applications such as Host Cell Protein contamination detection or in custom proprietary assays.
The success of our new products along with high quality and responsive customer service has resulted in us being ranked among the leaders in label-free technology. ForteBio quality is evidenced by our biosensor manufacturing plant in Shanghai achieving ISO 9001 certification. Now 90% of our biosensor shipments will be ISO certified. In five years, we have become #2 in the label-free market as claimed by SDi, a leading Life Science market analysis firm. Many of our customers have been the catalysts for our growth through their published research and industry presentations. I want to thank them for their belief in us.
As CEO, it is my responsibility to build a company that can be counted on to serve our customers and challenge our employees. Five years ago, we set out to establish ourselves with life science customers and today we are thriving as a vibrant, independent business achieving double digit top line growth, positive earnings and cash flow. Our balance sheet is healthy. We have no debt.
Leading ForteBio the past three years has been exciting and I look forward to the future when we expect to achieve our goal to become the label-free market leader.